Evidence network for deaths_(OS)

1EMILIA, 20121KATHERINE, 20191WJOG6110B/ELTOP, 20181SYSUCC-002, 20223KEYNOTE-119 (PDL1 CPS>1), 2019 KEYNOTE-119 (PDL1 CPS>10), 2019 KEYNOTE-119 (all population), 20192IMpassion-130 (all population), 2018 IMpassion-130 (PDL1>1%), 20181IMpassion-031 (all population), 20202IMpassion-131 (PD-L1 > 1%), 2020 IMpassion-131 (all population), 20201EMBRACA, 20181SOLAR-1 (patients with PIK3CA mutant status), 20191OlympiAD, 20171OlympiA (BIG 6-13, NSABP B-55), 01HER2CLIMB, 20203KEYNOTE-355 (all population), 2020 KEYNOTE-355 (CPS>1), 2020 KEYNOTE-355 (CPS>10), 20202ASCENT (all population), 2021 ASCENT (patients without brain metastases), 20211DESTINY Breast03, 20221DESTINY-Breast04, 20222PAKT (all population), 2020 PAKT (PIK3CA/AKT1/PTEN-altered), 20201LOTUS, 20171SOPHIA, 20211BrighTNess (velaparib-P-C (arm A) vs paclitaxel alone (arm C)), 20182NALA, 2020 NALA (brain metastases), 20201CLEOPATRA, 20121EGF104900, 20101CALGB 40302, 20141LUX-Breast 1, 20161AVEREL, 20131EGF30008 (HER2-positive), 20091PALOMA-3, 20161PENELOPE-B, 20211KCSG-BR15-10, 20191MONALEESA-2, 20161MONARCH 2, 20202E2112, 2021 ENCORE301, 20131PALOMA-1, 20161MONALEESA-3, 20182BELLE-2 (full population), 2017 BELLE-2 (patients with known PI3K status), 20171NCT02756364 (sapanisertib weekly), 20221NCT02187991 - HR-positive and HER2-negative cohort, 20211QUILT-2.015, 20131Huang, 2020placeboStandard of Care (SoC)placebo plus SoCpaclitaxel followed by doxorubicin plus cyclophosphamidecarboplatin plus nab-paclitaxelaromatase inhibitorfulvestranttrastuzumab plus capecitabinetrastuzumab emtansinelapatinib plus capecitabinechemotherapytrastuzumabtrastuzumab plus chemotherapyendocrine therapyvinorelbinelapatinib plus epirubicin and cyclophosphamide followed by docetaxeltrastuzumab plus docetaxelcapecitabinedoxorubicin plus cyclophosphamide followed by docetaxellapatinibGM-CSFtrastuzumab plus vinorelbineletrozolepertuzumab plus trastuzumab plus cyclophosphamideexemestanepaclitaxelexemestane plus ridaforolimustrastuzumab plus endocrine therapydurvalumab aloneneratinibpembrolizumab aloneatezolizumab plus nab-paclitaxelatezolizumab plus nab-paclitxel followed by doxorubicin plus cyclophosphamidepembrolizumab plus paclitxel followed by doxorubicin plus cyclophosphamideatezolizumab plus paclitaxelatezolizumab plus carboplatin plus nab-paclitaxeltalazoparibabemaciclib plus aromatase inhibitoralpelisib plus fulvestrantolaparibtucatinib plus trastuzumab plus capecitabinepembrolizumab plus SoCsacituzumab govitecantrastuzumab deruxtecancapivasertib plus paclitaxelipatasertib plus paclitaxelmargetuximab plus chemotherapypalbociclibveliparib plus paclitaxel plus carboplatininetetamab plus vinorelbineneratinib plus capecitabinetrastuzumab plus epirubicin and cyclophosphamide followed by docetaxelpertuzumab plus trastuzumab plus docetaxelpertuzumab plus trastuzumabdoxorubicin plus cyclophosphamide followed by docetaxel plus trastuzumablapatinib plus trastuzumablapatinib plus fulvestrantAE37 vaccine plus GM-CSFGP2 vaccine plus GM-CSFafatinib plus vinorelbinebevacizumab plus trastuzumab plus docetaxellapatinib plus letrozoledocetaxel plus carboplatin with trastuzumab followed by trastuzumabpalbociclib plus fulvestrantpalbociclib plus endocrine therapyribociclib plus letrozoleribociclib plus endocrine therapyabemaciclib plus fulvestrantabemaciclib plus endocrine therapyentinostat plus exemestanepalbociclib plus letrozoleribociclib plus fulvestrantbuparlisib plus fulvestranttaselisib plus letrozolesapanisertib plus fulvestrantdalpiciclib plus fulvestranttucidinostat plus exemestanealisertib plus paclitaxeldalotuzumab plus ridaforolimus plus exemestanealpelisib plus letrozoleganitumab plus endocrine therapyOBI-822/OBI-821 plus cyclophosphamidetrastuzumab emtasine plus endocrine therapymetformincelecoxib plus endocrine therapybuparlisib plus letrozolecediranib plus fulvestranteverolimusdirect evidencenetwork meta-analysis
T vs. C placeboStandard of Care (SoC)placebo plus SoCpaclitaxel followed by doxorubicin plus cyclophosphamidecarboplatin plus nab-paclitaxelaromatase inhibitorfulvestranttrastuzumab plus capecitabinetrastuzumab emtansinelapatinib plus capecitabinechemotherapytrastuzumabtrastuzumab plus chemotherapyendocrine therapyvinorelbinelapatinib plus epirubicin and cyclophosphamide followed by docetaxeltrastuzumab plus docetaxelcapecitabinedoxorubicin plus cyclophosphamide followed by docetaxellapatinibGM-CSFtrastuzumab plus vinorelbineletrozolepertuzumab plus trastuzumab plus cyclophosphamideexemestanepaclitaxelexemestane plus ridaforolimustrastuzumab plus endocrine therapydurvalumab aloneneratinibpembrolizumab aloneatezolizumab plus nab-paclitaxelatezolizumab plus nab-paclitxel followed by doxorubicin plus cyclophosphamidepembrolizumab plus paclitxel followed by doxorubicin plus cyclophosphamideatezolizumab plus paclitaxelatezolizumab plus carboplatin plus nab-paclitaxeltalazoparibabemaciclib plus aromatase inhibitoralpelisib plus fulvestrantolaparibtucatinib plus trastuzumab plus capecitabinepembrolizumab plus SoCsacituzumab govitecantrastuzumab deruxtecancapivasertib plus paclitaxelipatasertib plus paclitaxelmargetuximab plus chemotherapypalbociclibveliparib plus paclitaxel plus carboplatininetetamab plus vinorelbineneratinib plus capecitabinetrastuzumab plus epirubicin and cyclophosphamide followed by docetaxelpertuzumab plus trastuzumab plus docetaxelpertuzumab plus trastuzumabdoxorubicin plus cyclophosphamide followed by docetaxel plus trastuzumablapatinib plus trastuzumablapatinib plus fulvestrantAE37 vaccine plus GM-CSFGP2 vaccine plus GM-CSFafatinib plus vinorelbinebevacizumab plus trastuzumab plus docetaxellapatinib plus letrozoledocetaxel plus carboplatin with trastuzumab followed by trastuzumabpalbociclib plus fulvestrantpalbociclib plus endocrine therapyribociclib plus letrozoleribociclib plus endocrine therapyabemaciclib plus fulvestrantabemaciclib plus endocrine therapyentinostat plus exemestanepalbociclib plus letrozoleribociclib plus fulvestrantbuparlisib plus fulvestranttaselisib plus letrozolesapanisertib plus fulvestrantdalpiciclib plus fulvestranttucidinostat plus exemestanealisertib plus paclitaxeldalotuzumab plus ridaforolimus plus exemestanealpelisib plus letrozoleganitumab plus endocrine therapyOBI-822/OBI-821 plus cyclophosphamidetrastuzumab emtasine plus endocrine therapymetformincelecoxib plus endocrine therapybuparlisib plus letrozolecediranib plus fulvestranteverolimus
placebo---NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
Standard of Care (SoC)NA---NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
placebo plus SoCNANA---NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
paclitaxel followed by doxorubicin plus cyclophosphamideNANANA---NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
carboplatin plus nab-paclitaxelNANANANA---NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
aromatase inhibitorNANANANANA---NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
fulvestrantNANANANANANA---NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
trastuzumab plus capecitabineNANANANANANANA---NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
trastuzumab emtansineNANANANANANANANA---NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
lapatinib plus capecitabineNANANANANANANANANA---NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
chemotherapyNANANANANANANANANANA---NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
trastuzumabNANANANANANANANANANANA---NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
trastuzumab plus chemotherapyNANANANANANANANANANANANA---NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
endocrine therapyNANANANANANANANANANANANANA---NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
vinorelbineNANANANANANANANANANANANANANA---NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
lapatinib plus epirubicin and cyclophosphamide followed by docetaxelNANANANANANANANANANANANANANANA---NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
trastuzumab plus docetaxelNANANANANANANANANANANANANANANANA---NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
capecitabineNANANANANANANANANANANANANANANANANA---NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
doxorubicin plus cyclophosphamide followed by docetaxelNANANANANANANANANANANANANANANANANANA---NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
lapatinibNANANANANANANANANANANANANANANANANANANA---NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
GM-CSFNANANANANANANANANANANANANANANANANANANANA---NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
trastuzumab plus vinorelbineNANANANANANANANANANANANANANANANANANANANANA---NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
letrozoleNANANANANANANANANANANANANANANANANANANANANANA---NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
pertuzumab plus trastuzumab plus cyclophosphamideNANANANANANANANANANANANANANANANANANANANANANANA---NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
exemestaneNANANANANANANANANANANANANANANANANANANANANANANANA---NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
paclitaxelNANANANANANANANANANANANANANANANANANANANANANANANANA---NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
exemestane plus ridaforolimusNANANANANANANANANANANANANANANANANANANANANANANANANANA---NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
trastuzumab plus endocrine therapyNANANANANANANANANANANANANANANANANANANANANANANANANANANA---NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
durvalumab aloneNANANANANANANANANANANANANANANANANANANANANANANANANANANANA---NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
neratinibNANANANANANANANANANANANANANANANANANANANANANANANANANANANANA---NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
pembrolizumab aloneNANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA---NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
atezolizumab plus nab-paclitaxelNANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA---NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
atezolizumab plus nab-paclitxel followed by doxorubicin plus cyclophosphamideNANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA---NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
pembrolizumab plus paclitxel followed by doxorubicin plus cyclophosphamideNANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA---NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
atezolizumab plus paclitaxelNANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA---NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
atezolizumab plus carboplatin plus nab-paclitaxelNANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA---NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
talazoparibNANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA---NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
abemaciclib plus aromatase inhibitorNANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA---NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
alpelisib plus fulvestrantNANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA---NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
olaparibNANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA---NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
tucatinib plus trastuzumab plus capecitabineNANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA---NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
pembrolizumab plus SoCNANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA---NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
sacituzumab govitecanNANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA---NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
trastuzumab deruxtecanNANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA---NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
capivasertib plus paclitaxelNANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA---NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
ipatasertib plus paclitaxelNANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA---NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
margetuximab plus chemotherapyNANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA---NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
palbociclibNANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA---NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
veliparib plus paclitaxel plus carboplatinNANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA---NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
inetetamab plus vinorelbineNANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA---NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
neratinib plus capecitabineNANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA---NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
trastuzumab plus epirubicin and cyclophosphamide followed by docetaxelNANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA---NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
pertuzumab plus trastuzumab plus docetaxelNANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA---NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
pertuzumab plus trastuzumabNANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA---NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
doxorubicin plus cyclophosphamide followed by docetaxel plus trastuzumabNANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA---NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
lapatinib plus trastuzumabNANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA---NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
lapatinib plus fulvestrantNANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA---NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
AE37 vaccine plus GM-CSFNANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA---NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
GP2 vaccine plus GM-CSFNANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA---NANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
afatinib plus vinorelbineNANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA---NANANANANANANANANANANANANANANANANANANANANANANANANANANANA
bevacizumab plus trastuzumab plus docetaxelNANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA---NANANANANANANANANANANANANANANANANANANANANANANANANANANA
lapatinib plus letrozoleNANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA---NANANANANANANANANANANANANANANANANANANANANANANANANANA
docetaxel plus carboplatin with trastuzumab followed by trastuzumabNANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA---NANANANANANANANANANANANANANANANANANANANANANANANANA
palbociclib plus fulvestrantNANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA---NANANANANANANANANANANANANANANANANANANANANANANANA
palbociclib plus endocrine therapyNANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA---NANANANANANANANANANANANANANANANANANANANANANANA
ribociclib plus letrozoleNANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA---NANANANANANANANANANANANANANANANANANANANANANA
ribociclib plus endocrine therapyNANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA---NANANANANANANANANANANANANANANANANANANANANA
abemaciclib plus fulvestrantNANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA---NANANANANANANANANANANANANANANANANANANANA
abemaciclib plus endocrine therapyNANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA---NANANANANANANANANANANANANANANANANANANA
entinostat plus exemestaneNANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA---NANANANANANANANANANANANANANANANANANA
palbociclib plus letrozoleNANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA---NANANANANANANANANANANANANANANANANA
ribociclib plus fulvestrantNANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA---NANANANANANANANANANANANANANANANA
buparlisib plus fulvestrantNANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA---NANANANANANANANANANANANANANANA
taselisib plus letrozoleNANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA---NANANANANANANANANANANANANANA
sapanisertib plus fulvestrantNANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA---NANANANANANANANANANANANANA
dalpiciclib plus fulvestrantNANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA---NANANANANANANANANANANANA
tucidinostat plus exemestaneNANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA---NANANANANANANANANANANA
alisertib plus paclitaxelNANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA---NANANANANANANANANANA
dalotuzumab plus ridaforolimus plus exemestaneNANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA---NANANANANANANANANA
alpelisib plus letrozoleNANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA---NANANANANANANANA
ganitumab plus endocrine therapyNANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA---NANANANANANANA
OBI-822/OBI-821 plus cyclophosphamideNANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA---NANANANANANA
trastuzumab emtasine plus endocrine therapyNANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA---NANANANANA
metforminNANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA---NANANANA
celecoxib plus endocrine therapyNANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA---NANANA
buparlisib plus letrozoleNANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA---NANA
cediranib plus fulvestrantNANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA---NA
everolimusNANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA---

pathologies: 64,370,336,147,145,355,337,146,317,4,319,144,356,351,357,352,354,353,358,359,324,142,305,306,98,96,269,60,143,270,140,240,3 - treatments: 507,1040 result logic